抗肥満薬の世界市場：治療タイプ・薬剤タイプ・作用機序・投与経路・流通経路・地域別 (～2035年)

世界の抗肥満薬の市場規模は、2024年の271億6,230万米ドルから、予測期間中はCAGR 25.82%で推移し、2035年には3,268億9,690万米ドルに達すると予測されています。抗肥満薬とは、人々がより健康的な体重を達成し維持するのを助けるために用いられる医薬品治療を指します。これらは食欲抑制、代謝調整、栄養吸収抑制といったさまざまな仕組みで作用します。通常、生活習慣の改善だけでは肥満関連の健康問題を管理できない場合に推奨されます。

世界の抗肥満薬市場は大幅に拡大しており、その主な要因は肥満患者数の増加と積極的な政府の関与にあります。特に食生活の変化や身体活動の減少傾向が医療的解決策への需要を高めています。世界中の政府は、国民の意識向上プログラム、食事ガイドライン、食習慣の改善、減量活動への補助金といった施策を実施しています。

地域別分析

抗肥満薬市場における北米の優位性は、この地域を革新的な医薬品ソリューションの世界的リーダーのトップに位置づけています。米国企業は、GLP-1受容体作動薬や二重作用分子といった新しい薬剤クラスの導入で最前線に立っています。また、この地域は新しい医療技術を早期に受け入れる慣習を持ち、有利な償還制度が承認後の迅速な市場浸透を支えています。

欧州では、英国、デンマーク、ドイツなどで、肥満治療に関する研究開発費が増加しています。特にデンマークのNovo Nordiskの施設は、この地域を革新的治療の中心地としています。国境を越えた医療研究プロジェクトにより、試験データへのアクセスが早まり、開発段階が短縮されています。安全性と有効性が確認されれば、処方薬への依存度が高いこの地域では普及が容易です。さらに、薬物療法と食事・運動を組み合わせた個別化肥満治療プランの導入が進んでいます。

アジア太平洋地域の肥満問題は、国内外の企業がアジア人の遺伝的特徴や生活習慣に焦点を当てた臨床研究に多額の投資をする大きな要因となっています。日本や韓国の製薬会社は、現地の人々に副作用が少ない独自バージョンの薬剤を開発しています。政府は税制優遇や規制緩和で臨床試験を支援しています。また、注射剤よりも経口剤を好む患者が多いため、経口型抗肥満薬への需要が高まっています。多国籍企業にとって、この地域は安価な肥満治療薬を試す場ともなっています。

当レポートでは、世界の抗肥満薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 促進要因
  • 肥満の増加
  • 政府の取り組みと支援の強化
• 抑制要因
  • 副作用と安全性に関する懸念
• 機会
  • 非外科的肥満治療に焦点を当てる

第5章 市場要因分析

• ポーターのファイブフォースモデル
• COVID-19が世界の抗肥満薬市場に与える影響
• 市場動向
• 規制状況
• アンメットニーズ
• 疫学的評価
• ブランドとパイプラインの分析
• 価格分析

第6章 世界の抗肥満薬市場：治療タイプ別

• 概要
• 食欲抑制剤
  • セロトニン・ノルエピネフリン再取り込み阻害薬
  • 選択的セロトニン2C受容体作動薬
  • ノルエピネフリン・ドーパミン再取り込み阻害薬 (NDRI)
• リパーゼ阻害薬
• GLP-1受容体作動薬
• 併用薬
• その他

第7章 世界の抗肥満薬市場：薬剤別

• 概要
• 処方薬
• 市販薬

第8章 世界の抗肥満薬市場：作用機序別

• 概要
• 中枢作用型抗肥満薬
• 末梢作用型抗肥満薬

第9章 世界の抗肥満薬市場：投与経路別

• 概要
• 経口
• 皮下

第10章 世界の抗肥満薬市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• オンライン薬局

第11章 世界の抗肥満薬市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア
  • ロシア
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • マレーシア
  • タイ
  • インドネシア
  • その他
• 南米
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他

第12章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 公開企業の株式：サマリー
• 比較分析：主要企業の財務動向
• 主な展開・成長戦略

第13章 企業プロファイル

• ELI LILLY AND COMPANY
• ASTRAZENECA
• GSK PLC
• GELESIS
• CHEPLAPHARM ARZNEIMITTEL GMBH
• NOVO NORDISK A/S
• RHYTHM PHARMACEUTICALS, INC.
• KVK TECH, INC.
• CURRAX PHARMACEUTICALS LLC
• VIVUS LLC

第14章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 BRAND AND PIPELINE ANALYSIS
• TABLE 3 PRICING ANALYSIS
• TABLE 4 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 5 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 7 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 9 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS), BY REGION, 2019-2035 (USD BILLION)
• TABLE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR LIPASE INHIBITORS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 11 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR GLP-1 RECEPTOR AGONISTS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR COMBINATION DRUGS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 13 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 15 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 16 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR OVER-THE-COUNTER DRUGS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 17 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 18 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR CENTRALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 19 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR PERIPHERALLY ACTING ANTI-OBESITY DRUGS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 20 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 21 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ORAL, BY REGION, 2019-2035 (USD BILLION)
• TABLE 22 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR SUBCUTANEOUS, BY REGION, 2019-2035 (USD BILLION)
• TABLE 23 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 24 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019-2035 (USD BILLION)
• TABLE 25 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019-2035 (USD BILLION)
• TABLE 26 GLOBAL ANTI-OBESITY DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019-2035 (USD BILLION)
• TABLE 27 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
• TABLE 28 NORTH AMERICA ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 29 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 30 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 31 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 32 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 33 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 34 NORTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 35 US: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 36 US: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 37 US: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 38 US: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 39 US: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 40 US: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 41 CANADA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 42 CANADA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 43 CANADA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 44 CANADA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 45 CANADA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 46 CANADA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 47 EUROPE ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 48 EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 49 EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 50 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 51 EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 52 EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 53 EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 54 GERMANY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 55 GERMANY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 56 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 57 GERMANY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 58 GERMANY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 59 GERMANY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 60 FRANCE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 61 FRANCE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 62 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 63 FRANCE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 64 FRANCE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 65 FRANCE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 66 UK: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 67 UK: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 68 UK: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 69 UK: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 70 UK: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 71 UK: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 72 SPAIN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 73 SPAIN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 74 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 75 SPAIN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 76 SPAIN: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 77 SPAIN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 78 ITALY: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 79 ITALY: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 80 ITALY: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 81 ITALY: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 82 ITALY: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 83 ITALY: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 84 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 85 RUSSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 86 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 87 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 88 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 89 RUSSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 90 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 91 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 92 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 93 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 94 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 95 REST OF EUROPE: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 96 ASIA PACIFIC ANTI-OBESITY DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
• TABLE 97 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 98 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 99 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 100 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 101 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 102 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 103 CHINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 104 CHINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 105 CHINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 106 CHINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 107 CHINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 108 CHINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 109 INDIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 110 INDIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 111 INDIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 112 INDIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 113 INDIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 114 INDIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 115 JAPAN: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 116 JAPAN: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 117 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 118 JAPAN: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 119 JAPAN: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 120 JAPAN: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 121 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 122 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 123 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 124 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 125 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 126 SOUTH KOREA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 127 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 128 MALAYSIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 129 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 130 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 131 MALAYSIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 132 MALAYSIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 133 THAILAND: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 134 THAILAND: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 135 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 136 THAILAND: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 137 THAILAND: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 138 THAILAND: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 139 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 140 INDONESIA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 141 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 142 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 143 INDONESIA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 144 INDONESIA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 145 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 146 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 147 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 148 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 149 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 150 REST OF ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 151 SOUTH AMERICA ANTI-OBESITY DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
• TABLE 152 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 153 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 154 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 155 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 156 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 157 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 158 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 159 BRAZIL: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 160 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 161 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 162 BRAZIL: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 163 BRAZIL: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 164 MEXICO: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 165 MEXICO: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 166 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 167 MEXICO: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 168 MEXICO: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 169 MEXICO: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 170 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 171 ARGENTINA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 172 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 173 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 174 ARGENTINA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 175 ARGENTINA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 176 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 177 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 178 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 179 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 180 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 181 REST OF SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 182 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
• TABLE 183 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 184 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 185 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 186 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 187 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 188 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 189 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 190 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 191 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 192 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 193 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 194 GCC COUNTRIES: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 195 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 196 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 197 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 198 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 199 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 200 SOUTH AFRICA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 201 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2019-2035 (USD BILLION)
• TABLE 202 REST OF MEA: ANTI-OBESITY DRUGS MARKET, FOR APPETITE SUPPRESSANTS, BY TYPE, 2019-2035 (USD BILLION)
• TABLE 203 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2019-2035 (USD BILLION)
• TABLE 204 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2019-2035 (USD BILLION)
• TABLE 205 REST OF MEA: ANTI-OBESITY DRUGS MARKET, ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
• TABLE 206 REST OF MEA: ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
• TABLE 207 PRODUCT APPROVAL
• TABLE 208 MARKETING APPROVAL
• TABLE 209 PRODUCT EXPANSION
• TABLE 210 FACILITY LAUNCH
• TABLE 211 AQUISITION
• TABLE 212 AGREEMENT
• TABLE 213 ELI LILLY AND COMPANY: PRODUCTS OFFERED
• TABLE 214 ELI LILLY AND COMPANY: KEY DEVELOPMENTS
• TABLE 215 ASTRAZENECA: PRODUCT OFFERED
• TABLE 216 ASTRAZENECA: KEY DEVELOPMENTS
• TABLE 217 GSK PLC: PRODUCTS OFFERED
• TABLE 218 GELESIS: PRODUCT OFFERED
• TABLE 219 CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCTS OFFERED
• TABLE 220 NOVO NORDISK A/S: PRODUCTS OFFERED
• TABLE 221 NOVO NORDISK A/S: KEY DEVELOPMENTS
• TABLE 222 RHYTHM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
• TABLE 223 RHYTHM PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
• TABLE 224 KVK TECH, INC.: PRODUCTS OFFERED
• TABLE 225 CURRAX PHARMACEUTICALS LLC: PRODUCTS OFFERED
• TABLE 226 CURRAX PHARMACEUTICALS LLC: KEY DEVELOPMENTS
• TABLE 227 VIVUS LLC: PRODUCTS OFFERED
• TABLE 228 VIVUS LLC: KEY DEVELOPMENTS

LIST OF FIGURES

• FIGURE 1 GLOBAL ANTI-OBESITY DRUGS MARKET: STRUCTURE
• FIGURE 2 GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035) SOURCE: MRR ANALYSIS
• FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035)
• FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035)
• FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ANTI-OBESITY DRUGS MARKET
• FIGURE 6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE, 2024 & 2035 (USD BILLION)
• FIGURE 7 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY TREATMENT TYPE, 2024
• FIGURE 8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE, 2024 & 2035 (USD BILLION)
• FIGURE 9 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DRUG TYPE, 2024
• FIGURE 10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION, 2024 & 2035 (USD BILLION)
• FIGURE 11 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY MECHANISM OF ACTION, 2024
• FIGURE 12 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2035 (USD BILLION)
• FIGURE 13 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024
• FIGURE 14 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2035 (USD BILLION)
• FIGURE 15 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
• FIGURE 16 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 & 2035 (USD BILLION)
• FIGURE 17 GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY REGION, 2024 (%)
• FIGURE 18 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 19 NORTH AMERICA ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 20 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 21 EUROPE ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 22 ASIA PACIFIC: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 23 ASIA PACIFIC: MULTIPLE SCLEROSIS TREATMENT DEVICES TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 24 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 25 SOUTH AMERICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 26 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
• FIGURE 27 MIDDLE EAST AND AFRICA: ANTI-OBESITY DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 28 GLOBAL ANTI-OBESITY DRUGS MARKET PLAYERS: COMPETITIVE ANALYSIS,
• FIGURE 29 COMPETITOR DASHBOARD: GLOBAL ANTI-OBESITY DRUGS MARKET
• FIGURE 30 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 ELI LILLY AND COMPANY: SWOT ANALYSIS
• FIGURE 32 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 ASTRAZENECA: SWOT ANALYSIS
• FIGURE 34 GSK PLC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 GSK PLC: SWOT ANALYSIS
• FIGURE 36 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 NOVO NORDISK A/S: SWOT ANALYSIS
• FIGURE 38 RHYTHM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 39 RHYTHM PHARMACEUTICALS, INC.: SWOT ANALYSIS

Global Anti-Obesity Drugs Market Research Report by Treatment Type [Appetite Suppressants (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine Dopamine Reuptake Inhibitors), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others], by Drug Type (Prescription Drugs, Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs, Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global anti-obesity drugs market, valued at USD 27.1623 billion in 2024, is projected to reach USD 326.8969 billion by 2035, growing at a CAGR of 25.82% from 2025 to 2035. Anti-obesity drugs refer to pharmaceutical treatments aimed at helping people achieve and maintain a healthier body weight. They work through various mechanisms, including appetite suppression, metabolism regulation, or nutrient absorption reduction. Such medications are usually recommended when lifestyle interventions alone are insufficient to manage obesity-related health concerns.

The global anti-obesity drugs market is experiencing extensive expansion, which is primarily attributed to the rising obese cases and the active governmental participation. Lifestyle changes, especially the way food is consumed and the trend of less physical activity, have prompted a demand for medical solutions. All over the globe, governments are implementing tactics such as public awareness programs, dietary guidelines, changing food habits, and subsidies for weight reduction activities.

The WHO's Global Action Plan on Physical Activity and Acceleration Plan to Stop Obesity are resulting in the adoption of more stringent prevention and treatment outlines by member states. Drug companies are innovating with new drug developments. For example, the efficacy of Wegovy and Mounjaro has been very promising in clinical trials, showing that the drugs can be a real alternative to bariatric surgery. The U.S. FDA's recent clearances and quicker regulatory pathways are making the distribution easier, particularly in developing countries.

Safety issues have always been the main obstacles for users, such as cardiovascular risk, gastric troubles, and psychiatric side effects. There are times when drug-caused severe complications have made manufacturers stop production and withdraw the products. Hence, gaining the confidence of patients should be a healthcare priority currently. In any case, considering the upward trend for healthcare costs related to obesity, the bright scenario in which policy support, technological innovation, and health awareness combined to provoke the market's sustained strong growth in the next years.

Industry Segmentations

In terms of the drug type, the global market is classified into prescription drugs and over-the-counter drugs.

Oral and subcutaneous are part of the route of administration of the global anti-obesity drugs market.

Appetite suppressants, lipase inhibitors, GLP-1 receptor agonists, combination drugs, and others are the treatment type category of the global market. Appetite suppressants are further segmented into Serotonin Norepinephrine reuptake inhibitors, selective serotonin 2C receptor agonists, and Norepinephrine Dopamine Reuptake inhibitors.

Based on the mechanism in action, the global market is divided into centrally acting anti-obesity drugs and peripherally acting anti-obesity drugs.

The global anti-obesity drugs market is segmented by the distribution channel, comprising hospital, retail, and online pharmacies.

Regional Analysis

North America's supremacy in the anti-obesity drugs market is the main factor that keeps the region at the top of the list of global leaders in innovative pharmaceutical solutions. Companies based in the U.S. are at the forefront of introducing new drug classes such as GLP-1 receptor agonists and dual-action molecules. Moreover, this area is also advantaged by a good practice of early acceptance of new medical technologies. Favorable reimbursement strategies are the fuel for swift market infiltration after a drug has been approved.

Europe's R&D spending on obesity therapies has grown, primarily in countries such as the UK, Denmark, and Germany. Novo Nordisk's facilities in Denmark have paved the way for the area to be a center for revolutionary treatments. The cross-border healthcare research projects are allowing quicker access to the trial data, thus, the development stages are shorter. The public's reliance on prescription drugs is high, which is helpful in the dissemination once safety and effectiveness are verified. Besides, the region is witnessing a trend of personalized obesity treatment plans incorporating pharmacotherapy with diet and exercise.

The obesity problem in the Asia-Pacific region is a significant factor pushing domestic as well as global companies to pour a lot of money into clinical research focusing on the Asian genetic and lifestyle profiles. Japan's and South Korea's pharmaceutical companies are creating Japanese and South Korean versions of the same drug to reduce the side effects for local populations. Governments are supporting clinical trials by offering tax benefits and lessening the regulations. Some are interested in oral obesity drugs rather than injection forms, so that patients can be comfortable. So, the multinationals are taking the region as a place to test inexpensive obesity treatments.

The South American region is gradually becoming the hub of R&D collaborations. One of the reasons for this trend is the fact that Brazil is gaining ground as the best place to conduct obesity-related clinical trials due to the diversity of the patient pool. Moreover, local biotech startups are forming alliances with global pharmaceutical companies to co-create cost-effective therapies. Nations are trying to decrease the level of their reliance on imports by promoting the local drug production sector. The collaborations between the public and private sectors are taking place to facilitate the regulatory approvals for the revolutionary treatments. The research on weight loss drugs in this area is mainly done on patients suffering from metabolic syndrome, which indicates the concern of local health officials.

In the Middle East & Africa, research is often aimed at understanding obesity in relation to cultural and dietary habits unique to the region. Universities in Gulf countries are collaborating with pharmaceutical companies to study obesity genetics among Arab populations. Investments in local manufacturing facilities are increasing to reduce import costs. Partnerships with global leaders ensure technology transfer and skill development for regional scientists. Drug innovation here often includes patient education programs to boost long-term adherence.

Key Players

Major competitors in the global anti-obesity drugs market are Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC, Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, and CHEPLAPHARM Arzneimittel GmbH.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 RISING PREVALENCE OF OBESITY
  • 4.2.2 INCREASING GOVERNMENT INITIATIVES AND SUPPORT
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS AND SAFETY CONCERNS
• 4.4 OPPORTUNITY
  • 4.4.1 FOCUS ON NON-SURGICAL OBESITY TREATMENTS

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET
• 5.3 MARKET TRENDS
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 NORTH AMERICA
  • 5.4.2 EUROPE
  • 5.4.3 ASIA-PACIFIC
  • 5.4.4 LATIN AMERICA
  • 5.4.5 MIDDLE EAST AND AFRICA
• 5.5 UNMET NEEDS
• 5.6 EPIDEMIOLOGY ASSESSMENT
• 5.7 BRAND AND PIPELINE ANALYSIS
• 5.8 PRICING ANALYSIS

6 GLOBAL ANTI-OBESITY DRUGS MARKET, BY TREATMENT TYPE

• 6.1 OVERVIEW
• 6.1 APPETITE SUPPRESSANTS
  • 6.1.1 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
  • 6.1.2 SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS
  • 6.1.3 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)
• 6.2 LIPASE INHIBITORS
• 6.3 GLP-1 RECEPTOR AGONISTS
• 6.4 COMBINATION DRUGS
• 6.5 OTHERS

7 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE

• 7.1 OVERVIEW
• 7.2 PRESCRIPTION DRUGS
• 7.3 OVER THE COUNTER DRUGS

8 GLOBAL ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

• 8.1 OVERVIEW
• 8.2 CENTRALLY ACTING ANTI-OBESITY DRUGS
• 8.3 PERIPHERALLY ACTING ANTI-OBESITY DRUGS

9 GLOBAL ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 OVERVIEW
• 9.2 ORAL
• 9.3 SUBCUTANEOUS

10 GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 10.1 OVERVIEW
• 10.2 HOSPITAL PHARMACIES
• 10.3 RETAIL PHARMACIES
• 10.4 ONLINE PHARMACIES

11 GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 CANADA
• 11.3 EUROPE
  • 11.3.1 GERMANY
  • 11.3.2 FRANCE
  • 11.3.3 UK
  • 11.3.4 SPAIN
  • 11.3.5 ITALY
  • 11.3.6 RUSSIA
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
  • 11.4.2 INDIA
  • 11.4.3 JAPAN
  • 11.4.4 SOUTH KOREA
  • 11.4.5 MALAYSIA
  • 11.4.6 THAILAND
  • 11.4.7 INDONESIA
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 SOUTH AMERICA
  • 11.5.1 BRAZIL
  • 11.5.2 MEXICO
  • 11.5.3 ARGENTINA
  • 11.5.4 REST OF SOUTH AMERICA
• 11.6 MIDDLE EAST AND AFRICA
  • 11.6.1 GCC COUNTRIES
  • 11.6.2 SOUTH AFRICA
  • 11.6.3 REST OF MEA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 MARKET SHARE ANALYSIS, 2024
• 12.3 COMPETITOR DASHBOARD
• 12.4 PUBLIC PLAYERS STOCK SUMMARY
• 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.1.1 PRODUCT APPROVAL
  • 12.1.2 MARKETING APPROVAL
  • 12.1.3 PRODUCT EXPANSION
  • 12.1.4 FACILITY LAUNCH
  • 12.1.5 AQUISITION
  • 12.1.6 AGREEMENT

13 COMPANY PROFILES

• 13.1 ELI LILLY AND COMPANY
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCTS OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 ASTRAZENECA
  • 13.2.1 COMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 SWOT ANALYSIS
  • 13.2.6 KEY STRATEGIES
• 13.3 GSK PLC
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCT OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 SWOT ANALYSIS
  • 13.3.6 KEY STRATEGIES
• 13.4 GELESIS
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 KEY STRATEGIES
• 13.5 CHEPLAPHARM ARZNEIMITTEL GMBH
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCT OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 KEY STRATEGIES
• 13.6 NOVO NORDISK A/S
  • 13.6.1 COMPANY OVERVIEW
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 RHYTHM PHARMACEUTICALS, INC.
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 KVK TECH, INC.
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 CURRAX PHARMACEUTICALS LLC
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 KEY STRATEGIES
• 13.10 VIVUS LLC
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES

14 DATA CITATIONS